Benzinga | Apr 21, 2021 09:26AM EDT

Craig-Hallum Initiates Coverage On Fennec Pharmaceuticals with Buy Rating, Announces Price Target of $17

Craig-Hallum analyst Robin Garner initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy rating and announces Price Target of $17.